The device uses AI detection of colonic mucosal lesions during colonoscopy procedures, supporting in detecting and removing pre-cancerous lesions.
The device uses both white light imaging and linked color imaging. Additionally, the system was trained on images captured by Fujifilm endoscopy imaging equipment.
Fujifilm saw 17% higher adenoma per colonoscopy when compared to conventional colonoscopy. The company plans to make the device commercially available this spring after a market evaluation.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.